• Je něco špatně v tomto záznamu ?

Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF

G. Patti, M. Lucerna, I. Cavallari, E. Ricottini, G. Renda, L. Pecen, F. Romeo, JY. Le Heuzey, JL. Zamorano, P. Kirchhof, R. De Caterina,

. 2017 ; 69 (4) : 409-419.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031093

BACKGROUND: Diabetes is a known risk predictor for thromboembolic events in patients with atrial fibrillation (AF), but no study has explored the prognostic weight of insulin in this setting. OBJECTIVES: This study evaluated the differential role of insulin versus no insulin therapy on thromboembolic risk in patients with diabetes and AF. METHODS: We accessed individual patient data from the prospective, real-world, multicenter, PREFER in AF (European Prevention of thromboembolic events-European Registry in Atrial Fibrillation). We compared the rates of stroke/systemic embolism at 1 year according to diabetes status (no diabetes, diabetes without insulin therapy, diabetes on insulin therapy). RESULTS: In an overall population of 5,717 patients, 1,288 had diabetes, 22.4% of whom were on insulin. For patients with diabetes who were on insulin, there was a significantly increased risk of stroke/systemic embolism at 1 year versus either no diabetes (5.2% vs. 1.9%; hazard ratio: 2.89; 95% confidence interval: 1.67 to 5.02; p = 0.0002) or diabetes without insulin treatment (5.2% vs. 1.8%; hazard ratio: 2.96; 95% confidence interval: 1.49 to 5.87; p = 0.0019). Notably, rates of stroke/embolism were similar in patients with diabetes not receiving insulin versus patients without diabetes (hazard ratio: 0.97; 95% confidence interval: 0.58 to 1.61; p = 0.90). The selective predictive role of insulin-requiring diabetes was independent of potential confounders, including diabetes duration, and was maintained in various subpopulations, including the subgroup receiving anticoagulant therapy. CONCLUSIONS: In this cohort of anticoagulated patients with AF, the sole presence of diabetes not requiring insulin did not imply an increased thromboembolic risk. Conversely, insulin-requiring diabetes contributed most, if not exclusively, to the overall increase of thromboembolic risk in AF.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031093
003      
CZ-PrNML
005      
20171025122843.0
007      
ta
008      
171025s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jacc.2016.10.069 $2 doi
035    __
$a (PubMed)28126158
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Patti, Giuseppe $u Department of Cardiovascular Sciences, Campus Bio-Medico University of Rome, Rome, Italy. Electronic address: g.patti@unicampus.it.
245    10
$a Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF / $c G. Patti, M. Lucerna, I. Cavallari, E. Ricottini, G. Renda, L. Pecen, F. Romeo, JY. Le Heuzey, JL. Zamorano, P. Kirchhof, R. De Caterina,
520    9_
$a BACKGROUND: Diabetes is a known risk predictor for thromboembolic events in patients with atrial fibrillation (AF), but no study has explored the prognostic weight of insulin in this setting. OBJECTIVES: This study evaluated the differential role of insulin versus no insulin therapy on thromboembolic risk in patients with diabetes and AF. METHODS: We accessed individual patient data from the prospective, real-world, multicenter, PREFER in AF (European Prevention of thromboembolic events-European Registry in Atrial Fibrillation). We compared the rates of stroke/systemic embolism at 1 year according to diabetes status (no diabetes, diabetes without insulin therapy, diabetes on insulin therapy). RESULTS: In an overall population of 5,717 patients, 1,288 had diabetes, 22.4% of whom were on insulin. For patients with diabetes who were on insulin, there was a significantly increased risk of stroke/systemic embolism at 1 year versus either no diabetes (5.2% vs. 1.9%; hazard ratio: 2.89; 95% confidence interval: 1.67 to 5.02; p = 0.0002) or diabetes without insulin treatment (5.2% vs. 1.8%; hazard ratio: 2.96; 95% confidence interval: 1.49 to 5.87; p = 0.0019). Notably, rates of stroke/embolism were similar in patients with diabetes not receiving insulin versus patients without diabetes (hazard ratio: 0.97; 95% confidence interval: 0.58 to 1.61; p = 0.90). The selective predictive role of insulin-requiring diabetes was independent of potential confounders, including diabetes duration, and was maintained in various subpopulations, including the subgroup receiving anticoagulant therapy. CONCLUSIONS: In this cohort of anticoagulated patients with AF, the sole presence of diabetes not requiring insulin did not imply an increased thromboembolic risk. Conversely, insulin-requiring diabetes contributed most, if not exclusively, to the overall increase of thromboembolic risk in AF.
650    _2
$a senioři $7 D000368
650    _2
$a fibrilace síní $7 D001281
650    12
$a komplikace diabetu $7 D048909
650    _2
$a diabetes mellitus 1. typu $x komplikace $7 D003922
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a inzulin $x terapeutické užití $7 D007328
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prospektivní studie $7 D011446
650    _2
$a rizikové faktory $7 D012307
650    _2
$a tromboembolie $x etiologie $x prevence a kontrola $7 D013923
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lucerna, Markus $u Daiichi-Sankyo Europe, Munich, Germany.
700    1_
$a Cavallari, Ilaria $u Department of Cardiovascular Sciences, Campus Bio-Medico University of Rome, Rome, Italy.
700    1_
$a Ricottini, Elisabetta $u Department of Cardiovascular Sciences, Campus Bio-Medico University of Rome, Rome, Italy.
700    1_
$a Renda, Giulia $u G. d'Annunzio University of Chieti, Chieti, Italy.
700    1_
$a Pecen, Ladislav $u Institute of Informatics, Academy of Sciences of Czech Republic, Prague, Czech Republic.
700    1_
$a Romeo, Fabio $u Daiichi-Sankyo Italy, Rome, Italy.
700    1_
$a Le Heuzey, Jean-Yves $u Cardiology and Arrhythmology, Georges Pompidou Hospital, René Descartes University, Paris, France.
700    1_
$a Zamorano, Josè Luis $u Department of Cardiology, University Hospital Ramòn y Cajal, Madrid, Spain.
700    1_
$a Kirchhof, Paulus $u Institute of Cardiovascular Sciences, University of Birmingham and Sandwell and West Birmingham Hospitals and University Hospitals Birmingham NHS Trust, Birmingham, United Kingdom; Hospital of the University of Münster, Münster, Germany.
700    1_
$a De Caterina, Raffaele $u G. d'Annunzio University of Chieti, Chieti, Italy; Fondazione G. Monasterio, Pisa, Italy. Electronic address: rdecater@unich.it.
773    0_
$w MED00002964 $t Journal of the American College of Cardiology $x 1558-3597 $g Roč. 69, č. 4 (2017), s. 409-419
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28126158 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171025122925 $b ABA008
999    __
$a ok $b bmc $g 1254686 $s 992120
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 69 $c 4 $d 409-419 $i 1558-3597 $m Journal of the American College of Cardiology $n J. Am. Coll. Cardiol. $x MED00002964
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

    Možnosti archivace